Across TCGA pan-cancer cohorts, SIPA1L1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SIPA1L1 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SIPA1L1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SIPA1L1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where SIPA1L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	39	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	14	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.480	.018	12	view →
LUAD	OS	Tertile	All	0.611	1.000	.006	11	view →
GBM	DFS	Quartile	All	0.303	0.495	.031	3	view →
LSCC	DFS	Quartile	All	0.379	0.926	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: SIPA1L1 tumor-vs-normal RNA expression · all SIPA1L1 data types